Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 96

recruiting
3 968
countries
28
conditions
2 103

3 968 trials match your criteria

Biliary neoplasm

Recruiting

Study of MP0317 with durvalumab, gemcitabine and cisplatin combination therapy as first-line treatment for patients with advanced biliary tract cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

T-cell type acute leukaemia+2

Recruiting

Study of CART84 Treatment for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Systemic lupus erythematosus

Recruiting

Study of Mosunetuzumab Treatment in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab

Myelodysplastic syndrome

Recruiting

Study of momelotinib tablets in patients with anemia caused by low-risk myelodysplastic syndrome

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years

Glucose tolerance impaired

Recruiting

Evaluation of controlled-ileal-release nicotinic acid tablets compared to placebo for treating people with prediabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Non-small cell lung cancer+5

Recruiting

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab

Non-small cell lung cancer

Recruiting

Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Arteriosclerosis

Recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen

Depression

Recruiting

Study of psilocybin compared to personalized rTMS treatment in adults with treatment-resistant depression

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol

Plasma cell myeloma

Recruiting

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab

Neoplasm malignant

Recruiting

Study of BMS-986504 for patients with advanced or metastatic non-small cell lung cancer with homozygous MTAP deletion who have previously received treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.